# A Phase II Study of Docetaxel Plus Carboplatin in Chemonaive Hormone-Refractory Prostate Cancer (HRPC) Patients

> **NCT00675545** · PHASE2 · COMPLETED · sponsor: **National University Hospital, Singapore** · enrollment: 2 (actual)

## Conditions studied

- Hormone-Refractory Prostate Cancer

## Interventions

- **DRUG:** Docetaxel, Carboplatin

## Key facts

- **NCT ID:** NCT00675545
- **Lead sponsor:** National University Hospital, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2010-05
- **Final completion:** 2010-05
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2012-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00675545

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00675545, "A Phase II Study of Docetaxel Plus Carboplatin in Chemonaive Hormone-Refractory Prostate Cancer (HRPC) Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00675545. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*